Real-world (RW) study in patients (pts) with metastatic colorectal cancer (mCRC) with long-term responses to regorafenib in the USA.

被引：0
|
作者：
Kim, Richard D.
Pan, Xiaoyun
Ostojic, Helene
Zhang, Yiqiao
Lunacsek, Orsolya
Pisa, Federica
Peeters, Marc
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Bayer HealthCare Pharmaceut Inc, Real World Evidence Oncol, Whippany, NJ USA
[3] Bayer Consumer Care AG, Basel, Switzerland
[4] Bayer HealthCare Pharmaceut, Whippany, NJ USA
[5] Bayer AG, Real World Evidence Oncol, Berlin, Germany
[6] Antwerp Univ, Antwerp Univ Hosp, Edegem, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
281-5277-2622-5397; 281-318-9499; 283-237-255; 3282-206-4957-326-5009-2386; 4; 3; 2; 182; 250; 38092-25821; 38092-20285; 38092-18849;
D O I：
10.1200/JCO.2024.42.3_suppl.48
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：48 / 48
页数：1
相关论文
共 50 条
  • [41] Efficacy, safety and prognostic subgroups for outcome with regorafenib in patients with refractory metastatic colorectal cancer in the real-world setting: The CORE study
    Martinez-Lago, N.
    Carnero Lopez, B.
    de la Camara Gomez, J.
    Vazquez-Rivera, F.
    Fernandez Montes, A.
    Cousillas Castineiras, A.
    de Dios, N.
    Varela Ponte, R.
    Reboredo-Lopez, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S269 - S270
  • [42] Efficacy, treatment modalities, and safety of regorafenib in Chinese metastatic colorectal cancer patients: A multiple centers real-world study.
    Jiang, Zhichao
    Sun, Yongkun
    Zhang, Wen
    Liu, Ning
    Qiu, Wensheng
    Jiang, Tao
    Li, Sheng
    Sun, Ning
    Li, Xiaoyou
    Zhu, Liangjun
    Liu, Zimin
    Zhou, Ai-Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] Circulating angiogenesis-related markers as predictors of benefit from regorafenib in metastatic colorectal cancer (mCRC) patients (pts)
    Antoniotti, C.
    Marmorino, F.
    Pennati, M.
    Zaffaroni, N.
    Rossini, D.
    Borelli, B.
    Zucchelli, G.
    Moretto, R.
    Pietrantonio, F.
    Masi, G.
    Vannini, F.
    Colombo, C.
    Saettini, A.
    Gini, S.
    Delliponti, L.
    Pfanner, E.
    Brunetti, I.
    Falcone, A.
    Cremolini, C.
    ANNALS OF ONCOLOGY, 2017, 28 : 7 - 7
  • [44] Prevention of regorafenib related skin toxicity in refractory metastatic colorectal cancer (mCRC) patients (pts): a single institution experience
    Troiani, T.
    Sforza, V.
    Cardone, C.
    Nappi, A.
    Capasso, A.
    Martini, G.
    Napolitano, S.
    Zanaletti, N.
    Vitale, P.
    Vitiello, P.
    De Vita, F.
    Orditura, M.
    Ferrara, M. L.
    Ciardiello, F.
    Martinelli, E.
    ANNALS OF ONCOLOGY, 2016, 27
  • [45] Survival of patients (pts) with BRAF V600E mutated metastatic colorectal cancer (mCRC) treated with systemic therapy in a real-world setting
    Gotz, Moritz
    Kasper, Stefan
    Paul, Andreas
    Markus, Peter
    Schumacher, Brigitte
    Albers, David
    Rosery, Vivian
    Laue, Katharina
    Zaun, Gregor
    Kostbade, Karina
    Pogorzelski, Michael
    Schmid, Kurt Werner
    Schildhaus, Hans-Ulrich
    Wiesweg, Marcel
    Schuler, Martin
    Virchow, Isabel
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 65 - 66
  • [46] Prognostic score (REGOSCORE) for survival after Regorafenib (RE) treatment for patients (pts) with pretreated metastatic colorectal cancer (mCRC)
    Kramar, A.
    Paule, B.
    Burtin, P.
    Tougeron, D.
    Desseigne, F.
    Dourthe, L. M.
    Wallet, J.
    Etienne, P. L.
    Mineur, L.
    Becuwe, C.
    Maes, P.
    Dauba, J.
    Michel, P.
    Hollebecque, A.
    Linot, B.
    Morere, J. F.
    De la Fouchardiere, C.
    Phelip, J. M.
    Andre, T.
    Adenis, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S358 - S358
  • [47] Circulating angiogenesis-related markers as predictors of benefit from regorafenib in metastatic colorectal cancer (mCRC) patients (pts).
    Antoniotti, Carlotta
    Marmorino, Federica
    Pennati, Marzia
    Zaffaroni, Nadia
    Rossini, Daniele
    Borelli, Beatrice
    Zucchelli, Gemma
    Moretto, Roberto
    Pietrantonio, Filippo
    Masi, Gianluca
    Vannini, Francesca
    Colombo, Camilla
    Gini, Serenella
    Saettini, Alessandra
    Delliponti, Laura
    Brunetti, Isa Maura
    Pfanner, Elisabetta
    Falcone, Alfredo
    Cremolini, Chiara
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [48] Real-world study of cetuximab used every other week versus weekly in US patients with metastatic colorectal cancer (mCRC).
    Lamy, Francois-Xavier
    Batech, Michael
    Salim, Shaista
    Boutmy, Emmanuelle
    Pescott, Chris
    Ronga, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] Real-world adherence and treatment discontinuation with trifluridine/tipiracil (FTD-TPI) compared with regorafenib (REG) for the treatment of metastatic colorectal cancer (mCRC).
    Patel, Anuj K.
    Duh, Mei Sheng
    Barghout, Victoria E.
    Yenikomshian, Mihran Ara
    Xiao, Yongling
    Wynant, Willy
    Tabesh, Majid
    Fuchs, Charles S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States
    Nevala-Plagemann, Christopher
    Sama, Shashank
    Ying, Jian
    Shen, Jincheng
    Haaland, Benjamin
    Florou, Vaia
    Garrido-Laguna, Ignacio
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2023, 21 (03): : 257 - 264
12345